VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LFMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LFMDLifeMD, Inc.
$1.70$82M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLFMDFinancials

LifeMD, Inc. (LFMD) Income Statement

15Y historyFree accessUpdated daily

Revenue declined from $65.7M in 2025Q1 to $47.3M in 2026Q2 and operating margin stayed negative at -15.1% despite an 88.8% gross margin, indicating that SG&A growth has not been matched by top-line recovery.

Income StatementBalance SheetCash FlowRatios

LFMD Income Statement

Annual statement

LFMD Income Statement

LifeMD, Inc. (LFMD) annual income statement — 15-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Sales/Revenue188.94M194.06M212.45M152.55M119.03M92.88M37.29M12.47M8.32M5.05M5.24M1.22M714.16K808.36K673.78K743.83K
Revenue Growth %-25.13%-8.66%39.27%28.15%28.16%149.04%199.1%49.79%64.68%-3.51%329.79%70.67%-11.65%19.97%-9.42%-
Cost of Goods Sold29.65M39.29M24.07M18.9M18.67M18M8.86M2.53M1.97M1.48M1.95M247.77K172.85K181.3K125.62K241.26K
COGS % of Revenue-20.25%11.33%12.39%15.68%19.38%23.76%20.25%23.65%29.35%37.15%20.33%24.2%22.43%18.64%32.44%
Gross Profit159.28M154.76M188.39M133.65M100.37M74.88M28.43M9.94M6.36M3.57M3.29M971.09K541.31K627.06K548.16K502.56K
Gross Margin %84.31%79.75%88.67%87.61%84.32%80.62%76.24%79.75%76.35%70.65%62.85%79.67%75.8%77.57%81.36%67.56%
Gross Profit Growth %--17.85%40.96%33.16%34.03%163.36%185.95%56.46%77.96%8.46%239.06%79.4%-13.68%14.39%9.07%-
Operating Expenses180.91M162.43M204.53M148.14M143.81M129.18M86.25M12.83M8.41M4.64M4.47M1.23M1.07M1.17M1.09M1.08M
OpEx % of Revenue-83.7%96.27%97.11%120.82%139.09%231.28%102.92%101.05%91.77%85.28%101.19%150.13%145.17%161.5%145.05%
Selling, General & Admin154.52M144.01M175.68M128.15M125.33M122.08M84.01M11.31M8.41M4.64M4.47M1.21M1.07M1.17M1.09M1.08M
SG&A % of Revenue-74.21%82.69%84%105.29%131.44%225.27%90.75%101.05%91.77%85.28%99.22%150.13%145.17%161.5%145.05%
Research & Development1.94M7.35M9.51M6.06M2.97M948.16K446.75K222.88K120.54K0023.93K0000
R&D % of Revenue-3.79%4.48%3.97%2.5%1.02%1.2%1.79%1.45%--1.96%----
Other Operating Expenses4M11.07M19.34M13.93M15.51M6.16M1.79M1.3M-516.98K0000000
Operating Income-21.62M-7.67M-16.14M-14.49M-43.45M-54.3M-57.82M-2.89M-2.06M-1.07M-1.17M-262.22K-530.88K-546.41K-540.02K-576.37K
Operating Margin %-11.44%-3.95%-7.6%-9.5%-36.5%-58.47%-155.04%-23.18%-24.7%-21.12%-22.42%-21.51%-74.34%-67.59%-80.15%-77.49%
Operating Income Growth %-52.49%-11.43%66.65%19.99%6.09%-1900.94%-40.54%-92.61%9.12%-347.98%50.61%2.84%-1.18%6.31%-
EBITDA-13.58M-361.24K-6.65M-7.89M-39.68M-53.43M-57.42M-2.55M-1.86M-975.98K-1.14M-218.47K-473.9K-489.43K-483.05K-519.68K
EBITDA Margin %-7.19%-0.19%-3.13%-5.17%-33.33%-57.53%-153.97%-20.48%-22.35%-19.31%-21.78%-17.92%-66.36%-60.55%-71.69%-69.87%
EBITDA Growth %-227.29%94.57%15.67%80.12%25.74%6.95%-2148.31%-37.28%-90.62%14.46%-422.26%53.9%3.17%-1.32%7.05%-
D&A (Non-Cash Add-back)8.05M7.31M9.49M6.6M3.77M868.76K397.76K335.61K195.78K91.56K33.72K43.75K56.98K56.97K56.97K56.69K
EBIT-21.5M-8.83M-16.14M-14.81M-39.69M-58.3M-57.82M-2.89M-2.06M-1.28M-1.17M-134.96K-473K-282.08K-459.48K-498.87K
Net Interest Income123K-1.36M-2.18M-2.6M-1.28M-3.02M-1.67M-761.15K-354.39K-100.52K-48.61K-37.48K-4.68K-3.38K-3.37K-21.26K
Interest Income126.22K000000000000000
Interest Expense3.21K1.36M2.18M2.6M1.28M3.02M1.67M761.15K354.39K100.52K48.61K37.48K4.68K3.38K3.37K21.26K
Other Income/Expense123K-2.52M-2.18M-2.92M-1.21M-7.02M-2.58M-761.15K-354.39K-150.91K-48.61K89.78K53.19K260.95K77.18K56.24K
Pretax Income-21.5M-10.19M-18.33M-17.41M-44.66M-61.32M-60.4M-3.65M-1.48M-1.22M-1.22M-172.43K-477.69K-285.46K-462.85K-520.13K
Pretax Margin %-11.38%-5.25%-8.63%-11.41%-37.52%-66.02%-161.96%-29.28%-17.84%-24.11%-23.35%-14.15%-66.89%-35.31%-68.69%-69.93%
Income Tax13.9K45.72K402K428K360.7K7.7K122.5K-122.5K-124.7K-12.49K0-13.2K-17.2K-17.2K-17.2K-17.2K
Effective Tax Rate %-0.06%-0.45%-2.19%-2.46%-0.81%-0.01%-0.2%3.36%8.4%1.02%0%7.66%3.6%6.03%3.72%3.31%
Net Income-21.92M-7.11M-18.88M-20.6M-45.54M-60.9M-58.65M-3.14M-1.24M-1.21M-1.11M-61.99K-460.49K-268.26K-445.65K-502.93K
Net Margin %-11.6%-3.66%-8.89%-13.5%-38.25%-65.57%-157.26%-25.16%-14.91%-23.86%-21.14%-5.09%-64.48%-33.19%-66.14%-67.61%
Net Income Growth %-376.33%62.36%8.32%54.77%25.23%-3.84%-1769.4%-152.83%-2.89%-8.89%-1686.59%86.54%-71.65%39.8%11.39%-
Net Income (Continuing)-21.51M-10.23M-18.73M-17.84M-45.02M-61.32M-60.52M-3.53M-2.29M-1.38M-1.22M-159.23K-460.49K-268.26K-445.65K-502.93K
Discontinued Operations-409.26K3.13M00000000000000
Minority Interest001.44M2.06M-475.55K-1.03M-2.18M-141.06K-77.96K-259.08K-6.55K80.91K0000
EPS (Diluted)-0.46-0.23-0.53-0.70-1.57-2.27-4.24-0.36-0.14-0.14-0.16-0.01-0.07-0.04-0.08-0.07
EPS Growth %-204.7%56.6%24.29%55.41%30.84%46.46%-1077.78%-157.14%0%12.5%-87.05%-67.94%42.15%-15.25%-
EPS (Basic)--0.23-0.53-0.70-1.57-2.27-4.24-0.36-0.14-0.14-0.16-0.01-0.08-0.05-0.08-0.07
Diluted Shares Outstanding48.18M45.13M41.2M33.91M30.98M27.01M14.28M9.9M9.05M8.8M7.05M6.4M6.15M6.02M5.78M7.52M
Basic Shares Outstanding48.18M45.13M41.2M33.91M30.98M27.01M14.28M9.9M8.84M8.8M7.05M6.16M6.07M5.88M5.5M7.52M
Dividend Payout Ratio----------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses despite revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Growth Fading After 2025

Based on LifeMD's reported quarterly figures, revenue growth decelerated sharply from 48.8% year-over-year in 2025Q1 to a 24.0% decline in 2026Q2, with quarterly revenue falling from $65.7M to $47.3M over five quarters.

The reported figures suggest the growth phase that peaked in 2024 and early 2025 has reversed, with the year-over-year decline in 2026 pointing to weaker demand or a shift in the mix of revenue sources. The data does not disclose whether volume or pricing drove the contraction, so the durability of any recovery cannot be assessed from these figures alone. Investors should monitor whether the sequential decline stabilizes in subsequent quarters.

Gross Margin Expansion Masks Operating Losses

As reported in the financial statements, LifeMD's gross margin widened from 85.3% in 2024Q4 to 88.8% in 2026Q2, yet operating margin remained negative at -15.1% in the latest quarter.

The gross margin improvement suggests favorable product or channel economics at the unit level, but it does not translate into bottom-line profitability. The gap between gross margin and operating margin implies that the cost base sits largely in selling and administrative expense rather than in cost of goods. Investors should monitor whether gross margin expansion can eventually offset overhead without further revenue growth.

SG&A Absorbs Nearly All Gross Profit

Based on LifeMD's reported figures, SG&A of $41.7M in 2026Q2 consumed roughly 99% of the $42.0M gross profit, leaving an operating loss of $7.1M.

SG&A has remained elevated at roughly $35M to $46M per quarter across the ten-quarter window, even as revenue fell, which indicates limited operating leverage in the current cost structure. The reported figures suggest that overhead has not scaled down with the revenue decline, which may reflect fixed commitments or continued investment in customer acquisition. Without disclosure of the split between acquisition and administrative spending, the source of this rigidity cannot be determined from the data.

Persistent Losses Tempered by Small Profit Quarters

According to reported income statements, LifeMD posted net income in only two of ten quarters, with EPS swinging between -$0.20 and $0.01 and stock-based compensation between $2.1M and $4.2M per quarter.

The net income that appeared in 2025Q1 was driven by operating profit of $2.5M, but this was not sustained and reversed within the following two quarters. Stock-based compensation remains a recurring cost of several million dollars per quarter, which means reported losses are partly non-cash, though the figures do not indicate whether this offsets dilution concerns. The pattern suggests earnings quality is volatile and that single profitable quarters should not be extrapolated without confirmation of durable operating improvement.

Margin Strength Versus Shrinking Revenue Base

Based on LifeMD's reported figures, the bull case rests on an 88.8% gross margin, yet revenue has contracted for two straight quarters while operating losses of $7.1M in 2026Q2 persisted.

A bullish reading would emphasize the rising gross margin as evidence of pricing discipline or a richer product mix, but the reported figures suggest that gross profit dollars have fallen alongside revenue, weakening that argument. Short-side analysis would note that SG&A remains near $42M per quarter, so any further revenue decline mechanically deepens losses unless overhead is cut. The data does not show whether the revenue decline reflects temporary timing or structural demand loss, and that uncertainty warrants further investigation before any recovery thesis is accepted.

LFMD — Frequently Asked Questions

Quick answers to the most common questions about buying LFMD stock.

What was LifeMD, Inc.'s (LFMD) revenue in 2025?

For fiscal year 2025, LifeMD, Inc. (LFMD) reported total revenue of $194.1M. This represents a 25988.7% increase compared to $0.7M in 2011.

Is LifeMD, Inc. (LFMD) profitable?

LifeMD, Inc. (LFMD) reported a net loss of $7.1M for the fiscal year ending 2025.

What is LifeMD, Inc.'s operating profit margin?

LifeMD, Inc. (LFMD) reported an operating income of $-7.7M, resulting in an operating profit margin of -4.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is LifeMD, Inc.'s gross profit and gross margin?

LifeMD, Inc. (LFMD) generated $154.8M in gross profit for the year, representing a gross profit margin of 79.8%. This demonstrates the company's core pricing power and production efficiency.